Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofabrication & Biomanufacturing 2022

Stephanie Seidlits's Biography

Stephanie Seidlits, Associate Professor, Biomedical Engineering, University of Texas at Austin

Stephanie Seidlits joined the Department of Biomedical Engineering as an Associate Professor in 2021. Dr. Seidlits' research seeks to develop multifaceted therapies for the central nervous system that utilize biomaterial platforms to both model and directly alter the pathological microenvironment. She obtained a B.S. in Bioengineering from Rice University and went on to receive both M.S. and Ph.D. degrees in Biomedical Engineering from the University Texas at Austin under the mentorship of Dr. Christine Schmidt and Dr. Jason Shear. Dr. Seidlits then trained as an NIH NRSA post-doctoral fellow in Chemical and Biological Engineering at Northwestern University under the mentorship of Dr. Lonnie Shea. Dr. Seidlits was honored with an NSF CAREER Award, the 2019 Society for Biomaterials Young Investigator Award, a 2019 Biomedical Engineering Society Young Innovator in Cellular and Molecular Bioengineering, a 2020 Rising Star in Cellular and Molecular Bioengineering Award from the Biomedical Engineering Society and the 2020 UCLA Northrop Grumman Excellence in Teaching Award.

Stephanie Seidlits Image

Engineering Ex Vivo Models of Brain Cancer

Tuesday, 22 March 2022 at 11:00

Add to Calendar ▼2022-03-22 11:00:002022-03-22 12:00:00Europe/LondonEngineering Ex Vivo Models of Brain CancerBiofabrication and Biomanufacturing 2022 in

The Seidlits lab works to design matrix-mimetic biomaterials for engineering tissues of the central nervous system (CNS). We work with hyaluronic acid (HA), a major component of the extracellular matrix (ECM) in the CNS, as a base material to create ex vivo models of brain and tumor tissues. I will discuss our work modeling glioblastoma (GBM), the most lethal, yet common, cancer originating in the brain. We have developed HA-based culture platforms that provide a controlled experimental context in which to characterize how the ECM microenvironment facilitates GBM tumor aggression. These biomaterial-based cultures of patient-derived GBM cells can model several aspects of clinical tumors, including kinetics of acquired resistance to chemotherapies, metabolic changes, and vasculature-associated infiltration.

Add to Calendar ▼2022-03-21 00:00:002022-03-22 00:00:00Europe/LondonBiofabrication and Biomanufacturing 2022Biofabrication and Biomanufacturing 2022 in